Clinical trials
Asymptomatic Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 5 |
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mahidol University | 3 |
| University College Dublin | 3 |
| Department of Medical Research, Lower Myanmar | 2 |
| Erasmus Medical Center | 2 |
| Biruni University | 1 |
| Butantan Institute | 1 |
| Center for Innovation and Research Organization | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Hôpital Européen Marseille | 1 |
| Institute of Health Information and Statistics of the Czech Republic | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asymptomatic Infections | 30 |
| Malaria | 7 |
| COVID-19 | 3 |
| Malaria, Falciparum | 3 |
| Bacteriuria | 2 |
| Bacterial Infections | 1 |
| Clostridium Infections | 1 |
| Cross Infection | 1 |
| Escherichia coli Infections | 1 |
| Infections | 1 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.